ACM
PCVX icon

Aster Capital Management’s Vaxcyte PCVX Stock Holding History

Aster Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37
Closed -$1.4K – 1151
2026
Q1 		$1.4K Buy
+37
New +$2.01K ﹤0.01% 773
2025
Q4 		– Sell
-1,252
Closed -$45.1K – 1338
2025
Q3 		$45.1K Buy
+1,252
New +$41.5K 0.02% 516
2024
Q4 		– Sell
-4,173
Closed -$477K – 1418
2024
Q3 		$477K Buy
+4,173
New +$376K 0.1% 210

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Aster Capital Management's PCVX Position: Q2 2026 in Review

Aster Capital Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 37 shares — an estimated $1.4K sold.

Aster Capital Management first reported a position in PCVX in Q3 2024 and held it in 3 quarters. The position peaked at $477K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Aster Capital Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 37 Vaxcyte shares in Q2 2026, an estimated $1.4K.
  • Aster Capital Management first reported a position in Vaxcyte in Q3 2024 and held it in 3 quarters.
  • Aster Capital Management's Vaxcyte position peaked at $477K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.